HER2 staining intensity in HER2-positive disease: Relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2761-2766

  Zabaglo, L ^a,b   Stoss, O ^c   Ruschoff J ^c   Zielinski, D ^c   Salter, J ^a   Arfi, M ^d   Bradbury, I ^d   Dafni, U ^e,f   Piccart Gebhart, M ^g   Procter, M ^d   Dowsett, M ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GKTSM   (United Kingdom)

^c TARGOS Molecular Pathology GmbH   (Germany)

^d FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^e Frontier Science Foundation Hellas   (Greece)

^f UNIVERSITY OF ATHENS   (Greece)

^g JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Her2; Hera; IHC intensity; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

BREAST CANCER; HER2; HERA; IHC INTENSITY; TRASTUZUMAB;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84887060197     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt275     Document Type: Article

References (17)

1. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
2. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
3. Dowsett M, Procter M, McCaskill-Stevens W et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009; 27: 2962-2969.
4. Perez EA, Reinholz MM, Hillman DW et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010; 28: 4307-4315.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
6. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36.
7. Ernster VL. Nested case-control studies. Prev Med 1994; 23: 587-590.
8. Freund RJ, Wilson WJ, Sa P. Regression Analysis. London: Academic Press 2006.
9. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
10. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12: 236-244.
11. Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784.
12. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005; 97: 1808-1815.
13. Vranic S, Teruya B, Repertinger S et al. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 2011; 117: 48-53.
14. Tse CH, Hwang HC, Goldstein LC et al. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol 2011; 29: 4168-4174.
15. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29: 217-233.
16. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
17. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/ neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003; 95: 142-153.